Carbohydrates and neurotrophic factors: A promising partnership for spinal cord injury rehabilitation.

Carbohydrates Delivery platforms Neurotrophic factors Spinal cord injury Tissue engineering

Journal

Biomaterials advances
ISSN: 2772-9508
Titre abrégé: Biomater Adv
Pays: Netherlands
ID NLM: 9918383886206676

Informations de publication

Date de publication:
23 Sep 2024
Historique:
received: 11 07 2024
revised: 19 09 2024
accepted: 21 09 2024
medline: 28 9 2024
pubmed: 28 9 2024
entrez: 27 9 2024
Statut: aheadofprint

Résumé

Spinal cord injury (SCI) leaves a temporary or enduring motor, sensory, and autonomic function loss, significantly impacting the patient's quality of life. Given their biocompatibility, bioactivity, and tunable attributes, three-dimensional scaffolds frequently employ carbohydrates to facilitate spinal cord regeneration. These scaffolds have also been engineered to be novel local delivery platforms that present distinct advantages in the targeted transportation of drug candidates to the damaged spinal cord, ensuring the right dosage and duration of administration. Neurotrophic factors have emerged as promising therapeutic candidates, preserved neuron survival and encouraged severed axons repair, although their local and continuous delivery is believed to produce considerable spinal cord rehabilitation. This study aims to discuss breakthroughs in scaffold engineering, exploiting carbohydrates as an essential part of their structure, and highlight their impact on spinal cord regeneration and sustained neurotrophic factors delivery to treat SCI.

Identifiants

pubmed: 39332344
pii: S2772-9508(24)00297-8
doi: 10.1016/j.bioadv.2024.214054
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

214054

Informations de copyright

Copyright © 2024 Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest No conflict of interest, financial or other, exists.

Auteurs

Mehdi Sanati (M)

Department of Pharmacology and Toxicology, Faculty of Pharmacy, Birjand University of Medical Sciences, Birjand, Iran.

Mohammad Amin Manavi (MA)

Department of Pharmacology and Toxicology, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.

Marzieh Noruzi (M)

School of Pharmacy, Semnan University of Medical Sciences, Semnan, Iran.

Homayoon Behmadi (H)

Department of Pharmacology and Toxicology, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.

Tayebeh Akbari (T)

Department of Microbiology, Islamic Azad University, North Tehran Branch, Tehran, Iran.

Sara Jalali (S)

Department of Pharmacology and Toxicology, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.

Mohammad Sharifzadeh (M)

Department of Pharmacology and Toxicology, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran. Electronic address: msharifzadeh@sina.tums.ac.ir.

Mehdi Khoobi (M)

Department of Radiopharmacy, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran; Drug Design and Development Research Center, The Institute of Pharmaceutical Sciences (TIPS), Tehran University of Medical Sciences, 1417614411 Tehran, Iran. Electronic address: m-khoobi@tums.ac.ir.

Classifications MeSH